Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 2

recruiting
3 979
countries
28
conditions
2 106

101 trials match your criteria

Chronic kidney disease

Recruiting

Study of semaglutide and finerenone for kidney and blood vessel protection in adults with chronic kidney disease, with or without diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone

Type 1 diabetes mellitus+1

Recruiting

Study of semaglutide for weight loss in adults with type 1 diabetes and obesity

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo

Diabetic foot+1

Recruiting

Study on the Effect of Semaglutide on Healing Foot Ulcers in Patients with Type 2 Diabetes

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

Obesity+2

Recruiting

Study on the Effects of Semaglutide on Mood in Patients with Major Depressive Disorder and Overweight or Obesity

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Semaglutide

Obesity

Recruiting

Study of semaglutide treatment for adolescents with obesity caused by antipsychotic medications

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Semaglutide

Chronic kidney disease

Recruiting

Study on Dapagliflozin, Finerenone, and Semaglutide for Treating Chronic Kidney Disease in Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone

Type 2 diabetes mellitus

Recruiting

Study on Using Dapagliflozin, Semaglutide, and Finerenone to Prevent Heart and Kidney Complications in Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

Obesity

Recruiting

Study of Semaglutide for Weight Loss in Obesity Patients with Low Response After Bariatric Surgery

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

Obesity+1

Recruiting

Study on the Effects of Semaglutide and Diet on Physical and Heart Health in Patients with Obesity and Heart Failure

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

Coronary artery disease+2

Recruiting

Study on the Effects of Semaglutide, Dapagliflozin, and Metformin in Patients with Coronary Artery Disease and Prediabetes

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

HIV infection+1

Recruiting

Study on Semaglutide for Weight Loss in Patients with HIV and Obesity

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.